Lumacyte CEO on how real-time insight is driving down manufacturing failures and opening doors for more patients.

Rapid developments in gene-modified cell therapies, especially CAR T-cell therapies, has increased demand for fast and reliable analytics methods for research, in-process development, and ...

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

With the power of robotics and the personalized medicine expertise of one of Japan's top drugmakers, Astellas Pharma and Yaskawa Electric Corporation are setting off on a joint venture to help ...